fashion -WSS

fashion

author：hotspot 2025-09-30 18:08:31 - browse：97644

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout LOUD podcast: Merger Mondays, Ozempic panic

focus

WSS

Insmed lung disease drug hits target in key Phase 3 trial

What will save rural psychiatry services? Higher Medicaid payments

First Opinion Podcast: What happens when kids become caregivers?

There’s no way to know how good AI health technologies are

How clinical AI models' predictive power can degrade over time

European regulators recommend Amylyx's ALS drug be rejected

explore

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Dark money group runs ads on China biotech bill

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

State Dept. review finds Biden bears some blame for Afghanistan failures

Lab trade group sues FDA to halt regulation of lab

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: Merger Mondays, Ozempic panic

Medicare details structure of new drug price negotiation program

How should state employee insurance handle Wegovy?

focus

Nick Jonas talks about managing diabetes along with his career

iTeos Therapeutics debuts first data on TIGIT

Life sciences deals on track to hit lowest point since 2017

What will save rural psychiatry services? Higher Medicaid payments

Health insurers say they are turning to AI to cut costs, improve care

Prosthetic arm enables patients to feel the objects they grip

focus

focus

Wikipedia

hotspot